Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy
- 17 January 2002
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 4 (1), 38-45
- https://doi.org/10.1002/jgm.243
Abstract
Background A central triple‐stranded DNA structure created during HIV‐1 reverse transcription, the central flap, acts as a cis‐active nuclear import determinant of the HIV‐1 DNA genome. Insertion of the sequences responsible for formation of the central DNA flap into an HIV‐1‐derived vector strongly enhances its transduction efficiency. Methods HIV‐1 vectors with or without inclusion of the DNA flap and encoding the same melanoma polyepitope were constructed to transduce dendritic cells (DCs) and to evaluate their capacity for induction of melanoma‐specific cytotoxic T‐lymphocyte (CTL) responses ex vivo and in vivo. Results HIV‐1 vectors including the DNA flap transduced up to 100% of immature mouse and human DCs. Inoculation of HLA‐A2.1 transgenic mice with this flap vector elicited vigorous and multi‐specific long‐term anti‐melanoma CTL responses, whereas the parental vector lacking the flap sequence was less efficient. Furthermore, human DCs transduced ex vivo with the recombinant DNA flap vector displayed efficient multi‐specific primary human CTL responses against melanoma. Conclusion Lentiviral vectors including the DNA flap should be powerful tools both for active immunization and for the ex vivo priming of CTL for tumor immunotherapy. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- HIV-1 Genome Nuclear Import Is Mediated by a Central DNA FlapCell, 2000
- Transduction of Human PBMC-Derived Dendritic Cells and Macrophages by an HIV-1-Based Lentiviral Vector SystemMolecular Therapy, 2000
- H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesEuropean Journal of Immunology, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Sustained expression of genes delivered directly into liver and muscle by lentiviral vectorsNature Genetics, 1997
- HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout MiceThe Journal of Experimental Medicine, 1997
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.The Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- HIV-1 Reverse Transcription A Termination Step at the Center of the GenomeJournal of Molecular Biology, 1994
- Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow.Proceedings of the National Academy of Sciences, 1993